Vizgen, a Cambridge, Mass.-based life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, closed a $37m Series B financing. Joining Vizgen’s Board of Directors is Marijn Dekkers, Ph.D., Chairman and Founder of Novalis LifeSciences LLC, an investment and advisory firm for the life science industry. Dekkers brings over three decades of life science industry experience to support the Vizgen team, having previously served as CEO of Bayer AG and Thermo Fisher Scientific. The company intends to use the funds to accelerate growth and infrastructure expansion leading up to full commercial launch. The company’s MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.